Replimune Group, Inc.
REPLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Replimune Group, Inc. (REPL) is listed under Biotechnology. At a $1.42B market cap, Replimune Group, Inc. ranks as a small-cap company within healthcare. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Market Cap
$1.42B
Beta
0.94
P/E (TTM)
—
P/E (Fwd)
-7.38
EPS (TTM)
$-3.15
EPS (Fwd)
$-2.04
ROE
-134.3%
ROA
-51.3%
Cash
$195.3M
Total Debt
$112.0M
Free CF
-$171.7M
52W Change
158.4%
Annual Financials
Cash vs Debt
Where REPL stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, REPL finished 91.38% above its 150-day moving average ($8.35) and 87.34% above its 200-day moving average ($8.53). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is REPL overbought or oversold?
At the September 3, 2026 close, REPL's RSI(14) was 56.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $195.3M in cash and $112.0M in debt, REPL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$171.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -134.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Replimune Group, Inc.'s trajectory.